The connections between C75 and obesity drug-target pathways

Francis P. Kuhajda, Leslie E. Landree, Gabriele V. Ronnett

Research output: Contribution to journalArticlepeer-review


Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

Original languageEnglish (US)
Pages (from-to)541-544
Number of pages4
JournalTrends in Pharmacological Sciences
Issue number11
StatePublished - Nov 2005

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology


Dive into the research topics of 'The connections between C75 and obesity drug-target pathways'. Together they form a unique fingerprint.

Cite this